SAMS Response to the Biden Administration’s $2 Billion Investment in Biomanufacturing
WASHINGTON, September 15, 2022. – The Securing America’s Medicines and Supply (SAMS) Coalition applauds the Biden Administration’s commitment to investing $2 billion in American biomanufacturing. These funds will help secure the domestic supply chain for critical medical products, reward American innovation, and create jobs across the country.
The White House’s commitment to reshoring all elements of the medical supply chain is a recognition of the importance of reducing America’s reliance on overseas manufacturers at every stage of the production process. SAMS calls on the federal government to remain committed to supporting domestic manufacturers of critical medical products with further funding in the upcoming FY2023 federal budget.
About Securing America’s Medicines and Supply
Securing America’s Medicines and Supply (SAMS) is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States. SAMS seeks to drive the implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and supplies. SAMS supports U.S. patients, domestic healthcare security, and U.S. jobs.